Skip Navigation
Skip to contents

Journal of Microbiology : Journal of Microbiology

OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Articles

Page Path
HOME > J. Microbiol > Volume 58(6); 2020 > Article
Review
[MINIREIVEW] Anti-MRSA agent discovery using Caenorhabditis elegans-based high-throughput screening
Soo Min Kim 1, Iliana Escorbar 2, Kiho Lee 2, Beth Burgwyn Fuchs 2, Eleftherios Mylonakis 2, Wooseong Kim 1
Journal of Microbiology 2020;58(6):431-444.
DOI: https://doi.org/10.1007/s12275-020-0163-8
Published online: May 27, 2020
1College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea, 2Division of Infectious Diseases, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island, 02903, USA
Corresponding author:  Wooseong Kim , Tel: +82-2-3277-3372, 
Received: 30 March 2020   • Revised: 4 May 2020   • Accepted: 6 May 2020
next
  • 112 Views
  • 0 Download
  • 9 Web of Science
  • 10 Crossref
  • 10 Scopus
Full Article

Abstract

Staphylococcus aureus is a leading cause of hospital- and community- acquired infections. Despite current advances in antimicrobial chemotherapy, the infections caused by S. aureus remain challenging due to their ability to readily develop resistance. Indeed, antibiotic resistance, exemplified by methicillin- resistant S. aureus (MRSA) is a top threat to global health security. Furthermore, the current rate of antibiotic discovery is much slower than the rate of antibiotic-resistance development. It seems evident that the conventional in vitro bacterial growth-based screening strategies can no longer effectively supply new antibiotics at the rate needed to combat bacterial antibiotic-resistance. To overcome this antibiotic resistance crisis, screening assays based on host–pathogen interactions have been developed. In particular, the free-living nematode Caenorhabditis elegans has been used for drug screening against MRSA. In this review, we will discuss the general principles of the C. elegans-based screening platform and will highlight its unique strengths by comparing it with conventional antibiotic screening platforms. We will outline major hits from high-throughput screens of more than 100,000 small molecules using the C. elegans–MRSA infection assay and will review the mode-of-action of the identified hit compounds. Lastly, we will discuss the potential of a C. elegansbased screening strategy as a paradigm shift screening platform.

  • Cite this Article
    Cite this Article
    export Copy Download
    Close
    Download Citation
    Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
    Format:
    • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
    • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
    Include:
    • Citation for the content below
    [MINIREIVEW] Anti-MRSA agent discovery using Caenorhabditis elegans-based high-throughput screening
    J. Microbiol. 2020;58(6):431-444.   Published online May 27, 2020
    DOI: https://doi.org/10.1007/s12275-020-0163-8
    Close
Related articles
Journal of Microbiology : Journal of Microbiology
© The Microbiological Society of Korea.
TOP